Cartalax
Cartalax is a synthetic short-chain tripeptide (Ala-Glu-Asp) belonging to the class of Khavinson peptide bioregulators, investigated for its targeted effects on cartilage tissue and the musculoskeletal system. It has been studied for its potential role in chondrocyte regulation, joint tissue homeostasis, and connective tissue support in preclinical research models.
59,00 €
📦Also available in a stack · save up to 86,00 €
Bioregulator - Advancedsave 86,00 €View the stack →Cartalax - Cartilage & Joint Bioregulator Peptide
Description
Cartalax is a synthetic short peptide bioregulator composed of the tripeptide sequence Ala-Glu-Asp, developed within the Khavinson peptide research framework. It is investigated for its selective influence on cartilage tissue, particularly chondrocyte activity, matrix synthesis, and joint structural integrity in experimental models.
In preclinical studies, Cartalax has been observed to stimulate proliferation of chondrocytes, modulate expression of cartilage-specific genes such as aggrecan and type II collagen, and support the restoration of extracellular matrix components in aged or degenerated cartilage cultures. Its effects are linked to epigenetic regulation via interaction with promoter regions of genes governing chondrogenesis.
Additional research suggests Cartalax may exert anti-inflammatory and cytoprotective effects within joint tissue models, reducing markers of cartilage catabolism and oxidative stress, while supporting cellular renewal in age-related degenerative models.
Supplied as a lyophilized powder for reconstitution, Cartalax is intended exclusively for laboratory research applications focused on musculoskeletal aging, chondrocyte biology, and peptide-driven tissue regulation.
Clinical Status:
Cartalax is a research peptide bioregulator studied primarily in Russian preclinical and limited observational frameworks for cartilage and joint-related applications. It is not approved for medical use and remains restricted to experimental and laboratory research.
Evidence type:
Human RCT ☐ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory ☐
Mechanism of Action
Cartalax works as a short bioregulatory peptide that penetrates cellular and nuclear membranes, where it binds to specific regions of DNA and modulates gene expression in chondrocytes and connective tissue cells. By selectively activating genes involved in collagen type II synthesis, proteoglycan production, and chondrocyte differentiation, it has been observed to restore cartilage matrix integrity and reduce inflammatory signaling in experimental models of joint degeneration.
Benefits
- Cartilage Matrix Support:
Cartalax has been investigated for its influence on chondrocyte activity and extracellular matrix synthesis in cartilage tissue. Research models suggest the tripeptide modulates gene expression involved in type II collagen and proteoglycan production, supporting structural integrity of articular surfaces. This makes it a peptide of interest in studies focused on cartilage maintenance and joint tissue regeneration. - Joint Tissue Regeneration:
Experimental observations indicate that Cartalax may stimulate reparative processes in damaged joint structures, including ligaments and synovial tissues. By modulating fibroblast activity and supporting collagen organization, it has been studied for its role in age-related cartilage degeneration models. Research suggests potential applications in preclinical investigations of osteoarthritis and post-injury recovery. - Anti-Inflammatory Modulation:
Cartalax has been observed to influence pro-inflammatory cytokine expression, including IL-1β and TNF-α, in cartilage and connective tissue models. This modulation may help reduce inflammatory damage within joint environments, supporting a more favorable regenerative milieu. Research interest centers on its potential to complement other peptide bioregulators targeting inflammation pathways. - Chondrocyte Proliferation:
Studies suggest Cartalax supports chondrocyte viability and proliferation, key cellular processes for cartilage homeostasis. By upregulating genes associated with cellular renewal, the peptide is investigated for its role in maintaining functional cartilage architecture. This activity has been documented in cell culture and aged animal models exploring tissue resilience. - Connective Tissue Repair:
As a short peptide bioregulator, Cartalax has been studied for broader effects on connective tissue homeostasis, including tendon and ligament structures. Research models highlight its influence on collagen synthesis and fibroblast signaling, supporting tissue repair processes following mechanical or age-related stress. This positions it as a candidate in musculoskeletal regeneration research. - Age-Related Degeneration Research:
Cartalax is frequently investigated in gerontological models exploring cartilage and joint aging. Observations indicate it may help restore gene expression patterns characteristic of younger tissue, slowing degenerative shifts in extracellular matrix composition. This makes it relevant in studies focused on prolonging functional tissue integrity in aging research subjects. - Synergy with Bioregulator Peptides:
Research suggests Cartalax demonstrates complementary activity when studied alongside other Khavinson-class short peptides, such as Pinealon or Vesugen. Combined protocols have been evaluated for their effect on systemic tissue regeneration, with Cartalax contributing specifically to musculoskeletal targets. This positions it as a useful tool in multi-peptide research frameworks. - Mobility-Related Tissue Health:
By supporting cartilage structure and reducing inflammatory load in research models, Cartalax has been studied for its impact on overall joint mobility parameters. Animal models show improved movement metrics and reduced cartilage erosion following extended dosing protocols. These findings have made it a focal point in preclinical mobility and orthopedic research.
Research Data
| Study / Model | Reported effect |
|---|---|
| Cultured chondrocytes (in vitro) | ↑ proliferation rate and ↑ aggrecan and type II collagen expression |
| Aged rat cartilage tissue | ↓ apoptosis markers and partial restoration of cellular density |
| Osteoarthritis animal model | ↓ inflammatory cytokines (IL-1β, TNF-α) and improved joint mobility |
| Senescent fibroblast cultures | Modulated gene expression linked to extracellular matrix synthesis |
| Rat intervertebral disc model | ↑ proteoglycan content and reduced degenerative markers |
| Geroprotective rodent studies | Improved functional indices of connective tissue with age |
| In vitro genotoxicity assays | No mutagenic or cytotoxic effects observed at tested concentrations |
Stack Suggestions
Cartalax is often combined in research with:
- Cartalax + BPC-157 → Combines cartilage-targeted peptide regulation with broad tissue and tendon repair pathways.
- Cartalax + TB-500 → Supports connective tissue remodeling and joint mobility in musculoskeletal recovery models.
- Cartalax + GHK-Cu → Enhances extracellular matrix synthesis and collagen organization across cartilage and skin.
- Cartalax + Epitalon → Pairs cartilage-specific bioregulation with systemic longevity and telomere-related research pathways.
⚠ Stacks are for experimental design only; not safety or efficacy guidance.
Pen Dosage Chart
| Cartalax Pen 20 mg | |
| Volume | 2 mL |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.1 mg |
| Example(s) | 10 clicks = 1 mg |
Dosage & Protocols Variations
Standard Research Protocol
- Dose: 5 – 10 mg
- Duration: 10 – 20 days
- Frequency: Daily (SubQ or IM)
- Cycle Interval: 4 – 6 months off before repeating
- Goal / Description: Common protocol in cartilage and joint-tissue research models.
Therapeutic Research Protocol
- Dose: 10 – 20 mg
- Duration: 20 – 30 days
- Frequency: Daily, split into morning and evening administration
- Cycle Interval: 3 – 4 months off before repeating
- Goal / Description: Targeted regimen for advanced cartilage degeneration and osteoarthritis models.
Stacked Protocol (Cartalax + Pinealon)
- Dose: 5 – 10 mg Cartalax + 5 mg Pinealon
- Duration: 15 – 20 days
- Frequency: Daily
- Cycle Interval: 4 months off before repeating
- Goal / Description: Combined bioregulator approach for joint repair and systemic cellular renewal.
Possible Side Effects
Cartalax is generally well-tolerated in preclinical and limited human observational studies.
Reported side effects are rare and mild:
- Transient redness or irritation at the injection site.
- Mild local discomfort during initial administration.
- Occasional fatigue or drowsiness reported in sensitive subjects.
No evidence of hormonal, hepatic, or systemic adverse effects has been observed in available data.
Product Attributes
- CAS #: 1247113-86-1
- Molecular Formula: C12H20N4O8
- Sequence (AA): AED
- Molecular Weight: 332.31 g/mol
- PubChem CID: N/A (not indexed)
- Half-Life: ~20-30 minutes (rapid tissue uptake)
- Synonyms: AED peptide, Ala-Glu-Asp, Alanyl-Glutamyl-Aspartate, Khavinson cartilage bioregulator
- Type: Synthetic short-chain peptide bioregulator (tripeptide)
- Research Focus: Joint & Cartilage Health, Musculoskeletal Regeneration, Connective Tissue Support
Scientific References
- Peptidergic regulation of cell differentiation in 3D-cultures of tissues of skin, thymus, pancreas, and cartilage Animal | In vitro
- Peptide regulation of cell differentiation, proliferation, and renewal Animal | In vitro
- Short peptides regulate gene expression, protein synthesis and enhance life span Animal | In vitro
- Khavinson peptides regulate gene expression and protein synthesis: facts and hypotheses Observational | Animal | In vitro
- Tetrapeptide KED stimulates functional activity of vascular endothelial cells in monolayer In vitro
- Peptide bioregulation of aging: results and prospects Observational | Animal
- Short peptides and telomere length regulator hormone irisin Animal | In vitro
- Peptides and Aging Observational | Animal
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 8°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS Cold-Chain Transport Boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not generally support merchants in this field.
For this reason, we accept mainly Bank Transfers.
We also work with a crypto payment provider, and from time to time, card payments may be available depending on processor availability.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day, depending on the daily cut-off time.
Please note that we do not dispatch shipments on Fridays or on days before official public holidays. This is done to ensure that parcels can be delivered on the next working day and are not held in transit over weekends or holidays.
This method ensures compliance, security, and continuity of service for all customers across the EU.
Didn't find the answer to your question?
View all frequently asked questions
